NCT07160036 Repeatability of AO-SLO (Mona IIa) Technology and Cone Cell Density of Individuals Use Repeated Low-level Red-light Therapy
| NCT ID | NCT07160036 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruihua Wei |
| Condition | Myopia |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2025-09-20 |
| Primary Completion | 2025-11-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2025-09-20 with a primary completion date of 2025-11-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To explore the repeatability of AO-SLO (Mona IIa) technology and the difference of cone cell density between individuals who used or not used repeated low-intensity red light treatment
Eligibility Criteria
Inclusion Criteria: * 6 - 55 years old, gender not limited; Obtained informed consent. Exclusion Criteria: * Children with obvious strabismus and amblyopia * With congenital eye disease, such as congenital cataract, congenital retinal disease * Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome) * Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.) * Refractive medium opacity (such as corneal disease, crystal opacity, etc.) * Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP\>21mmHg or binocular IOP difference ≥5mmHg) * Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases * Optic nerve damage or congenital optic nerve dysfunction * Can not be regularly checked * The adjustment range is less than 8D or obvious near difficulties * Other reasons researchers think it is not suitable for inclusion in researchers
Contact & Investigator
Ruihua Wei
PRINCIPAL INVESTIGATOR
Tianjin Medical University Eye Hospital, Tianjin, Tianjin 120120 Recruiting
Frequently Asked Questions
Who can join the NCT07160036 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 55 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07160036 currently recruiting?
Yes, NCT07160036 is actively recruiting participants. Contact the research team at liuguihua1992@163.com for enrollment information.
Where is the NCT07160036 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07160036 clinical trial?
NCT07160036 is sponsored by Ruihua Wei. The principal investigator is Ruihua Wei at Tianjin Medical University Eye Hospital, Tianjin, Tianjin 120120 Recruiting. The trial plans to enroll 180 participants.